Albion Financial Group UT Increases Stake in Zoetis Inc. (NYSE:ZTS)

Albion Financial Group UT grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 37.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,793 shares of the company’s stock after purchasing an additional 485 shares during the quarter. Albion Financial Group UT’s holdings in Zoetis were worth $350,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Webster Bank N. A. raised its holdings in Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after acquiring an additional 82 shares during the period. Quarry LP boosted its stake in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the period. Neo Ivy Capital Management bought a new position in Zoetis in the 4th quarter worth about $40,000. LRI Investments LLC purchased a new position in Zoetis during the 1st quarter valued at about $43,000. Finally, Hazlett Burt & Watson Inc. increased its position in shares of Zoetis by 60.7% during the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after buying an additional 102 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. BTIG Research boosted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler boosted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, Stifel Nicolaus raised their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $220.38.

Zoetis Trading Up 0.1 %

ZTS stock opened at $190.31 on Friday. The company has a market capitalization of $86.22 billion, a PE ratio of 37.24, a price-to-earnings-growth ratio of 2.95 and a beta of 0.89. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company’s 50 day moving average price is $187.88 and its two-hundred day moving average price is $175.97.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter last year, the company earned $1.41 EPS. The firm’s revenue was up 8.3% compared to the same quarter last year. As a group, analysts predict that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.